content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 26, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
             Delaware                       000-14879              22-2322400
  ------------------------------    ------------------------   -------------------
   (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
         of Incorporation)                                     Identification No.)
  
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  ---------------------------------------------------------     ------------------
          (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  
  <PAGE>
  
  
  ITEM 5.02   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
              APPOINTMENT  OF  PRINCIPAL  OFFICERS; COMPENSATORY  ARRANGEMENTS  OF
              CERTAIN OFFICERS.
  
       On October 26, 2006,  Cytogen  Corporation  (the  "Company")  announced the
  appointment  of Kevin Bratton as the Company's new chief  financial  officer.  A
  finance  executive  with  more  than  35  years  of  experience  in  healthcare,
  biotechnology and technology, Mr. Bratton was previously chief financial officer
  at Metrologic  Instruments,  Inc. (NASDAQ:  MTLG), a global technology  company.
  During his tenure at  Metrologic,  Mr.  Bratton  directed the company's  finance
  operations during a period of significant growth in sales, net income, cash flow
  from operations, and working capital.
  
       Prior to joining  Metrologic  Instruments,  Mr.  Bratton  worked at The JPM
  Company,  where he served as chief  financial  officer  from 2000 to 2002 and as
  director of external  reporting  from 1999 to 2000.  Prior to joining  JPM,  Mr.
  Bratton  worked  for more than 20 years in the  healthcare  sector.  He was vice
  president  finance and treasurer for the  biotechnology  company IGI,  Inc., and
  corporate  controller for the specialty medical company Delmed, Inc. Mr. Bratton
  began his career with the public accounting firm Touche Ross & Co. (now Deloitte
  & Touche  LLP).  He has a bachelor of science in business  and  accounting  from
  Northeastern University.
  
       The full text of the October 26, 2006 press  release  issued in  connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
          Exhibit No.       Description
          -----------       -----------
  
             99.1           Press Release of the Company dated October 26, 2006.
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                CYTOGEN CORPORATION
  
  
  
                                                By: /s/ William J. Thomas
                                                   -------------------------------
                                                   William J. Thomas
                                                   Senior Vice President and
                                                     General Counsel
  
  Dated:   October 26, 2006
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
  
          Exhibit No.       Description
          -----------       -----------
  
             99.1           Press Release of the Company dated October 26, 2006.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8-k_cfo102606.txt", "description": "FORM 8-K RE CFO 102606", "secsgml_size_bytes": 5052}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "061166313"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 26, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                       000-14879              22-2322400
  ------------------------------    ------------------------   -------------------
   (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
         of Incorporation)                                     Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  ---------------------------------------------------------     ------------------
          (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 5.02   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
              APPOINTMENT  OF  PRINCIPAL  OFFICERS; COMPENSATORY  ARRANGEMENTS  OF
              CERTAIN OFFICERS.
  
       On October 26, 2006,  Cytogen  Corporation  (the  "Company")  announced the
  appointment  of Kevin Bratton as the Company's new chief  financial  officer.  A
  finance  executive  with  more  than  35  years  of  experience  in  healthcare,
  biotechnology and technology, Mr. Bratton was previously chief financial officer
  at Metrologic  Instruments,  Inc. (NASDAQ:  MTLG), a global technology  company.
  During his tenure at  Metrologic,  Mr.  Bratton  directed the company's  finance
  operations during a period of significant growth in sales, net income, cash flow
  from operations, and working capital.
  
       Prior to joining  Metrologic  Instruments,  Mr.  Bratton  worked at The JPM
  Company,  where he served as chief  financial  officer  from 2000 to 2002 and as
  director of external  reporting  from 1999 to 2000.  Prior to joining  JPM,  Mr.
  Bratton  worked  for more than 20 years in the  healthcare  sector.  He was vice
  president  finance and treasurer for the  biotechnology  company IGI,  Inc., and
  corporate  controller for the specialty medical company Delmed, Inc. Mr. Bratton
  began his career with the public accounting firm Touche Ross & Co. (now Deloitte
  & Touche  LLP).  He has a bachelor of science in business  and  accounting  from
  Northeastern University.
  
       The full text of the October 26, 2006 press  release  issued in  connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
          Exhibit No.       Description
          -----------       -----------
  
             99.1           Press Release of the Company dated October 26, 2006.
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                CYTOGEN CORPORATION
  
                                                By: /s/ William J. Thomas
                                                   -------------------------------
                                                   William J. Thomas
                                                   Senior Vice President and
                                                     General Counsel
  
  Dated:   October 26, 2006
  EXHIBIT INDEX
  
          Exhibit No.       Description
          -----------       -----------
  
             99.1           Press Release of the Company dated October 26, 2006.